Zynex Says FDA Clears M-Wave Neuromuscular Electrical Stimulation Device
(RTTNews) - Medical technology company Zynex, Inc. (ZYXI) announced Tuesday that it has received clearance from the U.S. Food and Drug Administration for the next generation M-Wave Neuromuscular Electrical Stimulation or NMES device.
NMES treatments have several uses, including aiding recovery from surgery, managing chronic conditions, and even enhancing exercise performance in healthy individuals.
The M-Wave replaces its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998.
The M-Wave is designed to improve the way patients manage their neuromuscular conditions. With advanced features and a user-friendly design, the M-Wave allows patients to be treated quickly in a clinical or home setting.
The compact and lightweight design of the M-Wave ensures portability and easy integration into patients' recovery routines.
DAX Retreats After Firm Start, Down Marginally
Swiss Franc Rises Against Majors
Sensex, Nifty Retreat On US Tariff Worries
Bank Of Korea Stands Pat On Rates, Lifts 2025 Growth Outlook
European Shares Mostly Higher As Nvidia Outlook Lifts Sentiment
Asian Shares Rise As Nvidia Beats Expectations
U.S. Dollar Falls Amid Fed Rate Cut Speculation
